[1] Smolen J S, Cohen S B, Tony H P, et al. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial[J]. Rheumatology (Oxford), 2021, 60(1): 256-262.
[2] Wu S, Wang Y, Zhang J, et al. Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis[J]. Afr Health Sci, 2020, 20(2):871-884.
[3] He Z, Wu R, Bai P, et al. Rituximab may cause higher mortality in young autoimmune disease patients with rituximab-induced interstitial lung disease: a case report and systematic review of the literature[J]. Int J Clin Pharmacol Ther, 2020, 58(12):740-748.
[4] Lioté H, Lioté F, Séroussi B, et al. Rituximab-induced lung disease: a systematic literature review[J]. Eur Respir J, 2010, 35(3): 681-687.
[5] Pellacani C, Eleftheriou G. Neurotoxicity of antineoplastic drugs: mechanisms, susceptibility, and neuroprotective strategies[J]. Adv Med Sci, 2020, 65(2):265-285.
[6] 石远凯, 孙 燕, 于金明, 等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J]. 中国肺癌杂志, 2016,19(1): 1-15.
[7] Tamiya A, Naito T, Miura S, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer[J]. Anticancer Res, 2012, 32(3):1103-1106.
[8] Kashiwada T, Saito Y, Terasaki Y, et al. Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer[J]. Jpn J Clin Oncol, 2019, 49(2):165-173.
[9] Shaw T, Quan J, Totoritis M C. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience [J]. Ann Rheum Dis, 2003, 62 (Suppl 2):ii55-ii59.
[10] Wu Y, Sun X, Liu J, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature[J]. Chin Neurosurg J, 2018, 4: 1.
[11] Malik S W, Myers J L, DeRemee R A, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns [J]. Am J Respir Crit Care Med, 1996, 154(6 Pt 1):1851-1856.
[12] Cong W, Liang Q, Li L, et al. Metabonomic study on the cumulative cardiotoxicity of a pirarubicin liposome powder[J]. Talanta, 2012, 89: 91-98.
[13] 邹外龙, 宋玉琴, 任 维, 等. 利妥昔单抗相关间质性肺炎50例临床分析[J]. 中华实用诊断与治疗杂志, 2021,35(1): 80-82.
[14] 黄 辰, 陆志伟, 杨玉琼, 等. 利妥昔单抗相关间质性肺疾病临床特点分析[J]. 中华结核和呼吸杂志, 2017, 40(10): 730-735.
[15] Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab[J]. Int J Hematol, 2008, 87(4): 393-397.
[16] 胡小龙. 利妥昔单抗诱导性肺损伤[J]. 临床肺科杂志, 2012,(8):1471-1473.
[17] Kamburova E G, Koenen H J, Boon L, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells [J]. Am J Transplant, 2012, 12(2): 341-350.